Post-Translational Regulation of Oct4 Transcriptional Activity by Saxe, Jonathan P. et al.
Post-Translational Regulation of Oct4 Transcriptional
Activity
Jonathan P. Saxe
1¤*, Alexey Tomilin
2, Hans R. Scho ¨ler
3, Kathrin Plath
4, Jing Huang
1*
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of
America, 2Institute of Cytology, Russian Academy of Science, St. Petersburg, Russia, 3Department of Cell and Developmental Biology, Max Planck Institute for Molecular
Medicine, Mu ¨nster, Germany, 4Department of Biological Chemistry and Broad Center for Regenerative Medicine, University of California Los Angeles, Los Angeles,
California, United States of America
Abstract
Oct4 is a key component of the molecular circuitry which regulates embryonic stem cell proliferation and differentiation. It is
essential for maintenance of undifferentiated, pluripotent cell populations, and accomplishes these tasks by binding DNA in
multiple heterodimer and homodimer configurations. Very little is known about how formation of these complexes is
regulated, or the mechanisms through which Oct4 proteins respond to complex extracellular stimuli which regulate
pluripotency. Here, we provide evidence for a phosphorylation-based mechanism which regulates specific Oct4 homodimer
conformations. Point mutations of a putative phosphorylation site can specifically abrogate transcriptional activity of a
specific homodimer assembly, with little effect on other configurations. Moreover, we performed bioinformatic predictions
to identify a subset of Oct4 target genes which may be regulated by this specific assembly, and show that altering Oct4
protein levels affects transcription of Oct4 target genes which are regulated by this assembly but not others. Finally, we
identified several signaling pathways which may mediate this phosphorylation and act in combination to regulate Oct4
transcriptional activity and protein stability. These results provide a mechanism for rapid and reversible alteration of Oct4
transactivation potential in response to extracellular signals.
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Introduction
The use of embryonic stem cells as therapeutics requires firm
understanding of the mechanisms that control their proliferation
and differentiation. To date, much progress has been made
towards identifying extrinsic and intrinsic regulators of these
processes. Studies have identified transcription factors such as
Stat3, Nanog, and Oct4 as being necessary for embryonic stem
(ES) cell self-renewal and maintenance of pluripotency. Likewise, it
has been shown that signaling pathways and transactivation
potentials triggered by extracellular stimuli such as BMPs, LIF,
and other factors play major regulatory roles (for review see [1,2]).
For instance, the role of LIF-gp130-Stat3 axis in promoting ES cell
proliferation is particularly well-defined [1,3], and BMP-induced
differentiation signals are inhibited by a Nanog-Smad1 protein
complex [4]; crosstalk between these pathways has also been
reported [5]. Several recent studies have shed light on transcrip-
tional networks controlled by factors such as Oct4 (for instance,
[6,7]), and begun to address the issue of how extracellular cues are
integrated with transcriptional circuits that maintain the plurip-
otent state [8]. Despite these findings, however, it is generally not
clear how extrinsic cues are integrated within the cell to control the
behavior of cell-intrinsic regulators of ES cell pluripotency such as
Oct4 [1].
Oct4 is a transcriptional regulator that can either activate or
repress target gene expression, depending on the cellular context
[9,10]. Oct4 messenger RNA is present in fertilized oocytes and
early embryos, and expression is maintained until mid-gastrulation
at which point it disappears, with the exception of primordial germ
cells and their progeny [11,12]. Oct4 expression is necessary for
the establishment of the inner cell mass of the blastocyst [13], and
proper levels of Oct4 expression are critical for maintenance of
pluripotency [14]. Using engineered ES cells, it has been shown
that increases or decreases of more than 50% of wild-type Oct4
mRNA levels is sufficient to induce differentiation towards
embryonic or trophectodermal lineages, respectively [14]. This
pattern is complemented by the phenotypes observed following
decreased Nanog expression; ES cells differentiate towards
endodermal fates upon Nanog loss-of-function [15], suggesting
that combinatorial functions of multiple proteins contribute to the
maintenance of pluripotency of ES cells partially through
inhibition of differentiation [16].
Oct4 has two distinct DNA binding domains which indepen-
dently bind half-sites of the canonical octamer motif. This
flexibility allows Oct4 to form heterodimers with other transcrip-
tion factors and to form homodimers in several conformations,
depending on the configuration of the octamer half-sites within the
DNA motif [17]. It has been shown that two such homodimers
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Hence, a potential phosphorylation event might be able to prevent
formation of one of these conformations while leaving the other
homodimer (as well as heterodimer formation potential) intact. As
all of these Oct4 homodimer and heterodimer conformations bind
distinct DNA motifs, a signaling-based mechanism could poten-
tially control the transcription of distinct subsets of Oct4 target
genes.
Through this mechanism, it would be possible for a cell to
couple extracellular cues to maintenance of pluripotency through
direct regulation of transcription factor activity, and to fine-tune
gene expression as the extracellular environment dictates. Here,
we provide evidence for such a phosphorylation-based mecha-
nism. Mutation of a potential protein kinase A (PKA) phosphor-
ylation site has dramatic consequences on Oct4 transactivation
potential. Surprisingly, small molecule activators of PKA signaling
increase expression of Oct4 protein, which in turn enhances
expression of a specific subset of Oct4 target genes. These effects
are mediated at least in part via p38 MAP kinase, thereby
providing multiple means for rapid control of Oct4 transactivation
in response to complex extracellular stimuli throughout early
development.
Results
Regulated degradation of Oct4 protein
Undifferentiated embryonic stem (ES) cells express Oct4 mRNA
and protein; this expression is rapidly downregulated during
embryoid body formation. Likewise, P19 cells induced to
differentiate via aggregation in the presence of retinoic acid also
turn off Oct4 expression rapidly following induction [19].
Substitution of dimethyl sulfoxide (DMSO) for retinoic acid
during P19 cell aggregation results in appearance of various
mesodermal cell types [20]. It was expected that differentiation
with DMSO would likewise cause a reduction in Oct4 mRNA
levels. Differentiation was induced as described in Materials and
Methods, and aggregates were plated and differentiated for an
additional eight days. Identical to previous reports [21], cultures
contained cells characteristic of DMSO-differentiated P19 cells
(data not shown). Oct4 mRNA expression was analyzed by semi-
quantitative RT-PCR. Surprisingly, however, Oct4 mRNA levels
did not decrease during differentiation with DMSO (Figure 1A).
To eliminate the possibility of any undifferentiated cells in the
cultures accounting for this observation, DMSO-differentiated
cells were treated with the anti-proliferative agent cytosine
arabinosidase (Ara-C), starting two days after aggregate plating.
Six days after the start of Ara-C treatment, cultures expressed
Oct4 mRNA at levels similar to undifferentiated cells (Figure 1B)
and exhibited morphology characteristic of endodermal cell types
(data not shown).
Analysis of Oct4 protein expression in differentiated Ara-C
cultures (DACs) showed a slight increase of Oct4 protein by day
four of aggregate formation (Figure 1C), consistent with previous
reports examining Oct4 mRNA dynamics [22] and the finding
that primitive endoderm differentiation is accompanied by a
transient increase in Oct4 protein levels [23]. Following aggregate
plating and Ara-C addition, Oct4 protein expression progressively
decreased, disappearing by day twelve. As these cultures still
express Oct4 mRNA (Figure 1A), we asked whether they are
synthesizing new Oct4 protein. We reasoned that if these cultures
are synthesizing new Oct4 protein, it must be rapidly degraded,
possibly in a proteasome-dependent manner [24]. Therefore,
twelve day old, DMSO-differentiated, Ara-C treated P19 cultures
were incubated with the proteasome inhibitors MG-132 and
lactacystin for four hours; this was sufficient to rescue Oct4 protein
expression (Figure 1D), suggesting that these cells do indeed
synthesize new Oct4 protein.
We then asked whether undifferentiated P19 cells also exhibit
this tight regulation of Oct4 protein levels. Cyclohexamide-
induced block of new protein synthesis shows that Oct4 protein
has a half-life of approximately 90 minutes in these cells
(Figure 1E), and treatment with 10 mM MG-132 for an hour
resulted in a significant increase in Oct4 protein levels (Figure 1F).
Hence, turnover of Oct4 protein is a dynamic process, with new
protein constantly replenishing older pools as they are degraded.
Previous work has shown that precise levels of Oct4 transcript and
protein are required for ES cell maintenance; raising or lowering
levels within a narrow window is sufficient to induce differentiation
or de-differentiation, respectively [14].
Figure 1. Oct4 protein is regulated via controlled degradation. (A) P19 cells were differentiated by aggregate formation in the presence of
DMSO (as described in Methods) for the indicated number of days, followed by RT-PCR analysis of Oct4 expression. (B) RNA was collected from
untreated P19 cells or cells differentiated as described above with the addition of 5 ug/mL cytosine arabinosidase (Ara-C), followed by RT-PCR
analysis. (C) P19 cells differentiated as above, in the presence of Ara-C and analyzed for expression of Oct4 protein. (D) Differentiated Ara-C treated
P19 cells were treated with indicated doses of proteasome inhibitors, followed by western blot analysis of Oct4 protein expression. (E)
Undifferentiated P19 cells were treated for indicated times with 20 ug/mL cyclohexamide, followed by western blot analysis of Oct4 expression. (F)
Undifferentiated P19 cells, untreated or treated with 10 uM MG-132 for 1 hour, followed by western blot analysis.
doi:10.1371/journal.pone.0004467.g001
Oct4 Posttranslational Control
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transactivation activity
One implication of these findings is that Oct4 may be subject to
post-translational modifications which alter its activity. To identify
sites for such modifications, we searched for potential regulatory
motifs using bioinformatic prediction algorithms (http://scansite.
mit.edu, [25]) and identified a putative protein kinase A (PKA)
phosphorylation site at S229 within the POUS domain of Oct4
(Figure 2A). As this residue lies on the edge of the POU
homeodomain, we asked if phosphorylation could influence the
transactivation potential of Oct4.
Flag-tagged point mutants which mimic (SRD) or prevent
(SRA) phosphorylation at this site were generated and co-
transfected into NIH 3T3 cells with Oct4 luciferase reporter
constructs. These constructs are activated by Oct4 monomers
(6xW) or homodimers in one of two distinct configurations (PORE
and MORE, due to different arrangements of the octamer
sequences within these motifs, see Discussion for details [10,26]).
As shown in Figure 2B, the S229A mutant behaved similar to WT
Oct4 (pcDNA3 vs WT, p,0.001 on PORE, MORE, and 6xW;
WT vs S229A, p.0.05 on PORE and 6xW, p,0.05 on MORE).
In contrast, the S229D mutant was unable to transactivate the
PORE reporter, but retained ability to activate (albeit at lower
levels) the other Oct4 reporters (pcDNA3 vs S229D, p.0.05 on
PORE, p,0.001 on MORE and 6xW; WT vs. S229D, p,0.001
on MORE, PORE, and 6xW) . These differences were not due to
changes in nuclear localization as tested by the distribution of GFP
fusions of these mutants (Figure 2D, an important consideration as
the PKA site lies on the edge of an identified nuclear localization
sequence [27]). Previously determined crystal structures of a
similar Oct-1 DNA binding domain have demonstrated that the
analogous residue is in close proximity to the interface between the
two molecules of the homodimer and DNA (and that this model is
conserved in Oct4 homodimers, [18]), suggesting that phosphor-
ylation at this residue may sterically hinder both DNA binding and
homodimer assembly (Figure 2C).
Also identified through this analysis was a potential Abl kinase
site at Y327 of Oct4. Mutation of this tyrosine to alanine or
phenylalanine resulted in hyperactive transactivation on all
reporter constructs tested (Figure 2E, S229A vs. Y327A,
p,0.001 on PORE and MORE, p,0.05 on 6xW; S229A vs.
Y327F, p,0.05 on PORE and MORE), suggesting that this site
may act to fine-tune Oct4 transcription through an undefined
mechanism.
Identification of a cohort of Oct4 target genes regulated
via a cAMP-responsive pathway
The fact that phosphorylation of Oct4 at S229 abolishes its
transactivation potential on the PORE sequence, but not other
octamer motif configurations, raises the possibility that this may be
a mechanism to regulate expression of those Oct4 target genes
controlled by a PORE sequence. However, only one gene with
such a sequence (osteopontin) is known to be an Oct4 target gene
[10]. To determine if this model could truly be biologically
Figure 2. Control of Oct4 dimerization via putative phoshorylation sites. (A) Schematic representation of Oct4 protein, highlighting the
predicted protein kinase A (PKA) site at S229. (B) Luciferase assays in 3T3 cells demonstrating activity of Oct4 point mutants on activation of different
reporter constructs. Data is normalized to CMV-renilla luciferase activity. (C) S229 phosphorylation of Oct4 can cause steric and electrostatic clashes
with the other Oct4 molecule in the PORE homodimer and with DNA binding. Crystal structure is PDB 1HF0. (D) Oct4 mutants fused to GFP do not
mis-localize to the cytoplasm. Cells were transfected with indicated constructs, and counterstained with DAPI and imaged 48 hours later. (E)
Luciferase assays as in (B) demonstrating the effects of mutation of Y327 to alanine or phenylalanine on indicated reporter constructs.
doi:10.1371/journal.pone.0004467.g002
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in the mouse genome by BLAST analysis. The PORE sequence is
15 nucleotides long; therefore, the chance of it randomly occurring
is approximately 1/1,000,000,000 (=4
15). Thus, this sequence
could occur by chance about three times in the 2.7610
9-bp mouse
genome. We found 652 exact, distinct occurrences in NCBI mouse
genome build 37.1. 411 of these matches were located within
250 kb of 348 annotated genes. Of these 411 matches, 156 were
10–100 kb away from annotated genes, 41 were located between
10 kb and the gene boundary, and 129 were found within the
genic sequence (Figure 3A, Table S1).
Upon filtering the list of 348 genes against lists of target genes
derived from whole-genome analysis studies of Oct4 binding
[6,28], 30 PORE genes were found to be bona fide Oct4 targets
(Table S2). Gene ontology (GO) analysis of genes within 250 kb of
a PORE sequence revealed enrichment in processes such as
transcription regulator activity (p,0.001), sex determination
(p,0.005), insulin receptor signaling (p,0.001), development
(p,0.0005), and protein phosphorylation (p,0.005). Binding of
Oct4 to several predicted PORE targets was verified via chromatin
immunoprecipitation (ChIP, Figure 3B). Thus Oct4 binding to the
PORE sequence is not an isolated event, and regulation of Oct4
binding specifically to this motif could be a major mechanism of
transcriptional control of stem cell self-renewal pathways.
We then tested whether PKA signaling can regulate transcrip-
tion of PORE genes. Treatment of P19 cells with the PKA
activator 8-Br-cAMP resulted in a large, rapid (,1 hour), and
transient (,8 hours) increase in Oct4 protein levels (Figure 3C).
This increase was accompanied by enhanced transactivation of
Oct4 luciferase reporters (Figure 4C) and increased chromatin
occupancy by Oct4 at native PORE (fgf12, p,0.01) and non-
PORE (Nanog, which is regulated by an Oct4/Sox2 heterodimer,
p,0.005) target genes (Figure 3D). The consequences of this
occupancy were then determined by RT-PCR analysis of a set of
Oct4 target genes following 8-Br-cAMP treatment. Provocatively,
genes controlled by Oct4 heterodimers (Oct4 itself, fgf4 [6,13])
showed either no increase or a slight decrease in transcript levels,
whereas those controlled by PORE homodimers (fgf12, osteo-
pontin, mIR-124a) generally displayed enhanced transcription
(Figure 3E and Figure S1, albeit with distinct kinetics).
p38 MAP kinase functions downstream of PKA to
regulate Oct4 activity
Brief stimulation with 8-Br-cAMP was sufficient to enhance
Oct4 protein levels; this enhancement was accompanied by
activation of the p38 MAP kinase pathway (Figure 4A), as
measured by western blotting. To test if enhanced p38 signaling
was simply correlated with or actively controlled levels of Oct4
protein, P19 cells were treated with the p38 MAPK inhibitor
SB202190. Inhibition of p38 activity resulted in a large and rapid
decrease in Oct4 protein levels (Figure 4B). In PORE reporter
assays in P19 cells, treatment with SB202190 alone caused a slight,
though statistically non-significant, decrease in reporter transacti-
vation; however, SB202190 was able to blunt 8-Br-cAMP-induced
reporter activation by ,33% (Figure 4C; p,0.001). Furthermore,
Figure 3. Specific regulation of a sub-set of Oct4 genes regulated by the PORE sequence. (A) BLAST analysis of the PORE sequence
reveals hundreds of potential binding sites within the mouse genome. Sites are organized by distance from known genes: extreme, .100 kb; distal,
between 10–100 kb; proximal, between 0–10 kb; intronic and exonic, within known genes. (B) Validation of fgf12 and PDE3A as bona fide Oct4
targets by chromatin immunoprecipitation with either serum (s, control) or monoclonal (1) or polyclonal (2) antibodies against Oct4. Nanog, positive
control. (C) Undifferentiated P19 cells were treated with 8-Br-cAMP for the indicated times and analyzed by western blotting. (D) Treatment with
1 mM 8-Br-cAMP for four hours enhances Oct4 binding to genomic loci as determined by chromatin immunoprecipitation, followed by real-time PCR
analysis at Nanog and fgf12 sites. Data is represented as the ratio of % precipitated DNA of input following precipitation with Oct4 antibody or rabbit
serum control, 6SD. (E) Undifferentiated P19 cells were treated with 1 mM 8-Br-cAMP for indicated times. Expression of multiple Oct4 target genes
controlled by Oct4/Sox2 heterodimers (1) or PORE-configuration homodimers (2) were assayed by RT-PCR.
doi:10.1371/journal.pone.0004467.g003
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induced Oct4 transcriptional activity (Figure 4D; 8-Br-treated
pcDNA3 vs. 8-Br-treated p38b,p ,0.05 ).
The discovery of EPAC as an additional intracellular cAMP
receptor [29], the finding that cAMP-induced PKA (but not
EPAC) signaling is coupled to the p38 MAPK pathway in some
cell types [30], and the observation that SB202190 partially, but
not completely, inhibited 8-Br-cAMP-stimulated Oct4 activity
(Figure 4D) led us to ask whether all of the 8-Br-cAMP response
was mediated through PKA/p38 MAPK. To address this issue,
highly specific cAMP analogues were used. N
6-Bnz-cAMP is
highly selective for PKA and does not activate EPAC. Conversely,
8-pCPT-O-Me-cAMP is selective for EPAC but does not stimulate
PKA [31]. In NIH 3T3 cells transfected with PORE reporter and
Oct4 expression constructs, overnight treatment with N
6-Bnz-
cAMP elicited a response ,50% of that obtained by treatment
with 8-Br-cAMP, at both the transcriptional (p,0.001 vs.
untreated and vs. 8-Br-cAMP) and protein levels (Figure 4E).
Treatment with 8-pCPT-O-Me-cAMP, in contrast, had no effect
on Oct4 reporter transactivation (p.0.05, untreated vs. 8-pCPT).
Surprisingly, co-treatment with N
6-Bnz-cAMP and 8-pCPT-O-
Me-cAMP elicited an effect equal to that of 8-Br-cAMP (Figure 4E;
8-Br-cAMP vs. N
6+8-pCPT, 37.2861.26 vs. 32.6063.13,
p.0.05; N
6 vs. N
6+8-pCPT, p,0.001), suggesting a synergistic
effect between PKA and EPAC activation on Oct4 transcriptional
activity and protein stability.
Discussion
In this paper, we describe a mechanism for regulation of a
subset of Oct4 target genes. Although transcriptional networks
controlled by Oct4 have been delineated [6,28,32] and several
protein interactors of Oct4 have been identified [24,33], the
mechanisms through which Oct4 protein itself is regulated have
largely remained unexplored.
Mechanisms for maintenance of steady-state levels of
Oct4 protein
Here, we exploit an unusual, previously noted property of
DMSO-differentiated P19 cells, namely the de-regulation of Oct4
transcription upon differentiation. It is well established that Oct4
mRNA and protein disappear relatively quickly following
differentiation of embryonic stem (ES) cells, by multiple protocols.
Similar results have been shown upon retinoic acid-induced
differentiation of P19 cells ([34], although re-appearance of low
levels of Oct4 mRNA [22] and protein [35] have been noted).
In contrast, previous studies have shown that Oct4 mRNA
levels can remain relatively stable during DMSO-induced
differentiation of P19 cells, although this has been ascribed to
undifferentiated, highly proliferative cells present in the cultures
following differentiation [22,34]. Here, we also observed little
change in Oct4 mRNA levels following DMSO-induced differen-
tiation, and we show that the transcript is present in differentiated,
non-proliferative cells (Figure 1B). Silencing of the Oct4 promoter
in P19 cells is a complex process, mediated by a combination of
events including orphan receptor binding, DNA methylation,
histone deacetylation, and heterochromatin formation [36,37]. It
is possible that the Oct4 expression patterns that we observe is due
to failure of one or more of these processes in the complex,
abnormal milieu of this embryonal carcinoma cell line during
differentiation.
Regardless, we were able to utilize this property to study
regulated turnover of Oct4 protein and further showed that our
results applied to undifferentiated, steady-state levels of Oct4.
Ubiquitination of Oct4 by a specific E3 ubiquitin ligase, with
resultant proteasomal degradation, has previously been described
[24]. Here, we confirm proteasomal turnover of intracellular Oct4
pools and also show that new Oct4 protein is continually
produced. As ES cells are exquisitely sensitive to changes in
Oct4 protein levels [14], this directly suggests that there must be
an active mechanism for marking existing Oct4 protein for
Figure 4. Regulation of Oct4-PORE activity by an 8-Br-cAMP-responsive pathway coupled to p38 MAP kinase. (A) P19 cells treated
with 1 mM 8-Br-cAMP for 1 hour followed by analysis of Oct4 expression and p38 MAP kinase phosphorylation. (B) Treatment of P19 cells with
indicated nM concentrations of the p38 MAP kinase inhibitor SB202190 for 30 minutes, followed by western blotting. (C) P19 cells were transfected
with control vector (tk-luc) or PORE reporter, followed by overnight treatment with indicated combinations of 0.5 mM 8-Br-cAMP and 200 nM
SB202190. (D) Luciferase assay in P19 cells following transfection with tk-luc or PORE reporters in combination with empty vector (pcDNA3) or p38b
MAPK expression vector, and overnight treatment with or without 0.5 mM 8-Br-cAMP. (E) Luciferase assay and western blot analysis of 3T3 cells
following transfection with PORE reporter and overnight treatment with indicated cAMP analogues.
doi:10.1371/journal.pone.0004467.g004
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modifications in regulation of Oct4 levels and, by extension,
maintenance of ES cell pluripotency.
Post-translational regulation of Oct4 may activate a
distinct set of target genes
As a first step towards identifying such post-translational
modifications, we performed bioinformatic analysis of the Oct4
protein sequence and identified several potential phosphorylation
sites. Previous studies have shown that the closely related Oct1 is
dynamically phosphorylated [38], and site-directed mutagenesis of
potential phosphorylation sites in Oct4 indicated a potential role
for phosphorylation in regulating homodimer complex formation
[18]. Oct4 contains two distinct DNA binding domains (the
POUH and POUS domains, each of which can bind to half of the
DNA octamer motif independently of the other) which are
separated by a flexible linker [39]; this in turn allows for
substantial leeway in arrangement of these domains in relation
to each other [17]. Oct4 can bind to the Octamer motif
(ATGCAAAT) as a monomer (in the Results section, this is
referred to as the 6xW reporter) or as a heterodimer with several
different proteins. In contrast, the PORE sequence (Palindromic
Oct factor Recognition Element, ATTTGAAATGCAAAT) was
originally identified in the first intron of osteopontin (OPN) and
cooperatively binds two Oct4 molecules; binding sites for
additional transcription factors such as Sox2 and Engrailed were
identified in close proximity [10]. Later analysis of Octamer
protein binding specificities revealed an additional DNA sequence,
the MORE (More PORE, ATGCATATGCAT), which likewise
binds two Oct4 molecules. As described in Tomilin et. al., the key
difference between the PORE and MORE sequences is that the
two DNA binding domains of Oct4 (the POUH and POUS
domains) which bind the octamer half-site originate from the same
protein molecule when bound to the PORE; in contrast, one
protein molecule contributes the POUH domain while the other
homodimer molecule contributes the POUS domain when binding
to the octamer half-site in the MORE configuration [26].
Thus, depending on arrangements of the octamer motif, and
presence of DNA motifs for additional transcription factors, Oct4
can form heterodimers with multiple partners or homodimers in
one of several unique conformations [17]. As detailed above, these
different conformations have corresponding consensus sequences
[10,26], and the Oct4 monomers interact with each other via
distinct protein faces depending on this sequence [18]. Hence,
phosphorylation (or other modifications) of sites on one interaction
face could potentially prevent DNA binding by one homodimer
configuration, while leaving binding of other configurations intact.
We found that mutation of serine 229 to aspartic acid, which
mimics phosphorylation at this site, does indeed prevent Oct4
transactivation potential of one homodimer conformation but not
of other Oct4 complexes. Based on the crystallographic structure
of the Oct1 DNA-binding domain (to which the Oct4 domain is
highly homologous), S229 is found to be positioned at the interface
between the POU-specific domain of one molecule and the POU-
homo domain of the other molecule of the homodimer, in direct
proximity to the DNA backbone (Figure 2C, [18]). Thus,
phosphorylation at this site likely causes steric and electrostatic
disruption of this specific Oct4 homodimer-DNA configuration
(the PORE homodimer), but not of the MORE homodimer
configuration or Oct4 heterodimer complexes.
BLASTing the 15-bp PORE sequence revealed a large cohort
of genes potentially regulated by such a mechanism (although
osteopontin, the one target gene previously known to be regulated
by a PORE sequence, was not identified in this analysis). Previous
whole-genome chromatin immunoprecipitation analyses have
identified a wide set of Oct4 target genes [6,28], as well as
describing co-occupancy of Oct4 and other transcription factors at
many of these genes [6]. Although low, the overlap between our
data set and those previously generated (6.2%) was quite similar to
the overlap between the previously generated data sets themselves
(8.1%, [28]), and may reflect 1) the possibility that only a limited
set of Oct4 targets are in proximity to a PORE sequence, and 2)
potential low genomic coverage in our search. Additional
predicted gene targets were verified to bind Oct4 in situ, and
targets were found to be enriched in several developmental and
molecular processes by gene ontology analysis. Thus, control of
homodimer formation could be a major mechanism for regulating
transcription of a diverse sub-set of Oct4 target genes.
Signaling pathways which regulate PORE-dependant
transcription
Signaling pathways which contribute to regulation of Oct4
stability and transactivation have not been identified previously;
indeed, this area remains a conspicuous ‘‘black box’’ in our
understanding of the circuitry which controls pluripotency. In
Oct4, S229 is predicted to be phosphorylated by protein kinase A
(PKA); therefore, we tested the effects of the PKA activator 8-Br-
cAMP and found that stimulation resulted in a rapid and transient
increase in Oct4 protein levels in P19 cells (although sustained
increases were observed in 3T3 cells, e.g. Figure 4E), with no effect
on Oct4 mRNA levels. This increase was accompanied by
enhanced chromatin occupancy and PORE-dependent transcrip-
tion of Oct4 targets (Figure 3D–E).
As a test of this model, that these potential Oct4 phosphory-
lation events can shape the ES cell transcriptional landscape, Oct4
point mutants in an inducible expression vector can be stably
transfected into ES lines which conditionally express wild-type
Oct4 [14]. Upon shutting off wild-type Oct4 expression, the effects
of these Oct4 point mutations on ES cell proliferation,
differentiation potential, and gene expression could be deter-
mined. Such experiments would potentially reveal a role for the
proposed phosphorylation event in regulating Oct4 activity and
provide further insight into how the Oct4 transcriptional network
regulates pluripotency.
Several studies have examined Oct4 genetic [6,28] and protein
[33] networks. One important outcome of these studies is the
observation that Oct4 and its protein binding partners form
complex auto-regulatory circuits in which Oct4, Sox2, and Nanog
proteins bind to each other’s promoters. This auto-feedback
system has been proposed as a feature of robustness, i.e. minor
perturbations to the system will not produce major effects on gene
transcription. Our data support and extend this idea. Despite
highly elevated levels of Oct4 protein following treatment with 8-
Br-cAMP, no change in transcription of genes controlled by Oct4
heterodimers (i.e. Oct4 itself, FGF4) was observed. This in turn
suggests that stoichiometric control of transcription factor levels
may provide robustness to this system. Thus, in the case of genes
which are not subject to this stoichiometric, multivariate
regulation (i.e. FGF12, osteopontin), absolute increases in levels
of the single required protein should be sufficient to enhance
transcription. Indeed, we found that putative PORE-containing
genes were robustly activated following 8-Br-cAMP treatment
(albeit with distinct patterns).
We further demonstrate that the cAMP-responsive enhance-
ment of Oct4 activity is at least partially regulated through the p38
MAP kinase pathway. Previous studies [30,40] revealed coupling
of p38 MAPK signaling to cAMP signaling, which was largely
mediated through activation of PKA. We found that specific
Oct4 Posttranslational Control
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while stimulation of EPAC by itself had little effect on Oct4,
simultaneous activation of EPAC and PKA strongly enhanced the
effects observed following stimulation of either pathway individ-
ually. PKA and p38 MAPK signaling have not generally been
explored in regulation of stem cell pluripotency or self-renewal.
Our findings that these pathways directly modify Oct4 activity
warrant further investigation of these signaling events in control of
these processes.
Materials and Methods
Cell Culture
P19 cells were cultured in alpha-minimal essential medium
(Invitrogen, Carlsbad CA) supplemented with 7.5% calf serum and
2.5% fetal bovine serum (Invitrogen). Differentiation was induced
by plating 1610
6 cells in a bacterial-grade 10 cm dish with 5%
FBS (Invitrogen) and 1% DMSO (Sigma, St. Louis MO). Media
was replenished on the second day and aggregates were plated on
plastic 10 cm dishes on the fourth day. Media was changed every
second day. In some experiments, cytosine arabinoside (Sigma)
was added to 5 mg/ml. 3T3 cells were cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10%
FBS.
Transfections
For luciferase assays, P19 cells were plated in 24-well plates at
1.0610
5 cells/mL in the media described above and transfected
with 0.8 mg total DNA containing 400 ng luciferase reporter and
1 ng pRL. In some experiments, 4 ng expression vector was
included. Total DNA was held constant by addition of
pBSSKII(+). Cells were transfected overnight and media was
changed the next day. Indicated drug treatments were started at
least four hours after final media change. For 3T3 cell
transfection, 1.5610
5 cells/mL were plated in 24-well plates in
0.5 mL DMEM+10% FBS. The next day, media was changed to
0.5 mL DMEM (no serum) and cells were transfected with
0.8 mg total DNA, containing 1 ng Oct4 expression plasmid,
100 ng luciferase reporter construct and 25 pg pRL (Promega),
and balanced with pBSSKII(+), for four hours followed by
addition of 0.6 mL/well DMEM+20% FBS. Media was changed
to 0.5 mL/well DMEM+10% FBS the next day. For Oct4-GFP
fusion overexpression, cells were plated in 4-well Chamber slides
(Nunc) and transfected with 1.6 mg total DNA, containing 0.8 mg
Oct4-GFP fusions, as described above. Cells were fixed with 4%
paraformaldehyde for 10 minutes and counter-stained with
DAPI.
Luciferase assays
48 hours after transfection, cells were lysed with 100 mL/well
16 passive lysis buffer (PLB, Promega) for 15 minutes with
shaking. 5 mL of each lysate was transferred to a white 384 well
plate (Corning) and assayed by addition of 25 mL Luciferase Assay
Reagent (LAR, Promega) and 25 mL Stop&Glo Reagent (Pro-
mega). Data was collected on an Analyst HT 384 well plate reader
(LJL Biosystems). In some cases, leftover lysate was spun briefly
and mixed 3:1 with LDS western blot loading buffer (Invitro-
gen)+b mercaptoethanol, heated at 70uC for 10 minutes and
stored at 220uC until use.
RNA Collection and RT-PCR
RNA was collected using an RNeasy kit (Qiagen) and DNA
digestion was performed with RQ1 DNase (Promega). One mg
RNA was used for cDNA synthesis with random hexamers
(Roche) and SuperScript II reverse transcriptase (Invitrogen).
cDNA was amplified using Taq DNA Polymerase (Invitrogen)
using exon-flanking and intron-spanning primers. The primer
sequences used were as follows:
Oct4up 59-tggagactttgcagcctgag-39
Oct4down 59-tgaatgcatgggagagccca-39
GAPDHup 59-accacagtccatgccatcac-39
GAPDHdown 59-tccaccaccctgttgctgta-39
fgf4up 59-GACACGAGGGACAGTCTTCTGGAG-39
fgf4down 59-CCGTTCTTACTGAGGGCCATGAA-39
OPNup 59-TTGCGCCACAGAATGCTGTGT-39
OPNdown 59- CTGTGGCATCAGGATACTGTTCATC-39
fgf12up 59-GGCGATACAGGGTTGAGGAATAG-39
fgf12down 59-TGGGACCAAGGACGAAAACAG-39
mIR-124a2-up 59-ATCAAGATCAGAGACTCTGCTCTC-39
mIR-124a2-down 59-TTCAAGTGCAGCCGTAGGCTC-39
Samples were run for 19–35 cycles (depending on primer set)
with annealing at 58uC and 30 second extensions (60 for Oct4) at
72uC. Densitometry was performed using Kodak MI software
(Kodak, Rochester NY).
Western blot analysis
Cells were washed with ice-cold PBS, lysed for 15 minutes on
ice with M-PER protein extraction reagent (Pierce), scraped, and
spun at 14,000 rpm for 10 minutes at 4uC. In some experiments,
protein concentrations were measured by Bradford assay. Lysates
were mixed with LDS loading buffer as described above, and ran
on 10% SDS-PAGE gels. Following transfer, PDVF membranes
were blocked for one hour with 10% nonfat milk in PBS with
0.1% Tween-20 (PBST) and incubated overnight with primary
antibody. The following primary antibodies were used: Oct4 (BD
Transduction Laboratories, 1:1000), phospho-p38 MAPK and
total p38 MAPK (Cell Signaling), b-Actin clone AC-15 (Sigma
Aldrich, 1:5000) and GAPDH (Ambion, 1:40,000). The next
days, blots were washed three times for five minutes each with
PBST, incubated with HRP-conjugated goat anti-mouse or anti-
rabbit secondary antibody (Pierce), washed again, and exposed
with ECL reagent (Amersham). Blots were stripped with Pierce
Restore western blot stripping buffer for 30 minutes at room
temperature.
Chromatin immunoprecipitation
Confluent 10 cm plates were fixed with 1% PFA at room
temperature for 10 minutes, lysed in SDS lysis buffer (50 mM
Tris, 10 mM EDTA, 1% SDS, Roche Complete protease
inhibitors, pH 8.1), scraped and collected into 1.5 mL microcen-
trifuge tubes, and DNA was sonicated to 200–800 bp fragments
with a Branson Sonifier 250 set to 30% power/90% duty, four
10 second pulses. Tubes were kept on ice for .1 min. between
pulses. Samples were spun down at 13,000 rpm for 10 minutes at
4uC and diluted 1:10 with ChIP dilution buffer (167 mM NaCl,
16.7 mM Tris pH 8.0, 1.2 mM EDTA, 1.1% Triton X-100,
0.01% SDS). Lysates were pre-cleared with Protein A-agarose
beads blocked with 2.5 mg/mL sonicated salmon sperm DNA
(Sigma-Aldrich) and 0.1% bovine serum albumin (BSA, Santa
Cruz Biotechnology). Small aliquots were removed for input
fractions. Protein-DNA complexes were then immunoprecipitated
overnight with polyclonal Oct4 antibody (sc-9081, Santa Cruz
Biotechnology), a mix of monoclonal Oct4 antibodies (BD
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normal serum controls (Pierce) on a rotator at 4uC.
The next day, complexes were isolated by incubation with
Protein A beads (described above) for one hour at 4uC with
rotation. Beads were washed sequentially in lo-salt buffer (150 mM
NaCL, 20 mM Tris pH 8.0, 2 mM EDTA, 1% Triton X-100,
0.1% SDS), hi-salt buffer (500 mM NaCl, 20 mM Tris pH 8.0,
2 mM EDTA, 1% Triton X-100, 0.1% SDS), and LiCl wash
buffer (10 mM Tris pH 8.0, 1 mM EDTA, 1% sodium deoxy-
cholic acid, 1% NP-40, 0.25 M LiCl), followed by two washes in
ice-cold TE, all for five minutes with rotation at 4uC. Chromatin
was eluted in elution buffer (1% SDS, 0.1 M NaHCO3),
2610 minutes. Cross-links were reversed by addition of 200 mM
NaCl and heating for 4 hours at 65uC. Proteins were digested with
Proteinase K (American Bioanalytical, Natick MA) and DNA was
purified by phenol-chloroform extraction and ethanol precipita-
tion. DNA was dissolved in H20 and used for analysis. The
following primer sequences were used:
Nanogup 59-GTCTTTAGATCAGAGGATGCCCC-39
Nanogdown 59-CTACCCACCCCCTATTCTCCCA-39
fgf12up 59-AAGCCATCTCCCCAGACAAGAATA-39
fgf12down 59-GCTGATGGAGCACAATGACTATGA-39
PDE3Aup 59-ATCAACCAAAGAGGACACAAGGAG-39
PDE3Adown 59-CCCAAAAACTAAAAGAGCAGAGCG-39
Samples were run for 25–35 cycles at 60uC annealing with
30 second extensions at 72uC. For real-time PCR analysis, 1 mLo f
chromatin was used as template in triplicate reactions using
FastStart SYBR Green Mastermix (Roche, Indianapolis IN) on a
CFX96 real-time PCR detection system (Bio-Rad, Hercules CA).
C(t)s were automatically assigned by the software and confirmed
by manual examination of the fluorescence data. The % of input
for each sample was calculated for normalization and the ratio of
(% input Oct4)/(% input NRS) for each condition was calculated.
Melting curve analyses confirmed the specificity of amplified
products.
Drug treatments
Before all treatments, media was changed four hours before
initiation. For proteasome inhibitor experiments, differentiated
cells were treated with indicated concentrations for four hours.
Undifferentiated cells were treated for 1 hour. Lactacystin, MG-
132, and SB202190 were from Calbiochem. 8-Br-cAMP was from
Sigma-Aldrich. N
6-Bnz-cAMP and 8-pCPT-29-O-Me-cAMP were
obtained from Axxora LLC (San Diego CA).
Bioinformatic analyses
Phosphorylation sites were predicted using Scansite 2.0 (http://
scansite.mit.edu; [25]) set on high stringency. For BLAST analysis,
the canonical PORE sequence (ATTTGAAATGCAAAT) and an
alternate sequence known to bind Oct4 (ATTTGAAAGG-
CAAAT, [18]) were used with the BLASTN program to query
the mouse genomic+transcript database with parameters opti-
mized for short, nearly exact matches with word size set to 15.
Gene information, including name and distance from PORE
occurrence, was manually curated.
For comparison with lists generated from previous studies, gene
identifiers were downloaded and pooled from supplemental data
lists, and converted to common identifiers using the DAVID gene
ID conversion tool (http://david.abcc.ncifcrf.gov), Matchminer
utility (http://discover.nci.nih.gov/matchminer/index.jsp; [41])
and WebGestalt Gene Set Analysis Toolkit (http://bioinfo.
vanderbilt.edu/webgestalt; [42]). Multiple conversions were per-
formed to enhance coverage as completely as possible. Analysis of
overlaps between the merged ChIP and PORE lists, and resulting
gene ontologies, were performed with WebGestalt.
Molecular modeling
Protein database coordinates for the Oct1/PORE structure
reported in ([18], PDB accession #1HF0) were visualized using
UCSF Chimera package (http://www.rbvi.ucsf.edu/chimera)
from the Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by
NIH P41 RR-01081 [43]).
Statistical analysis
Data are expressed as mean6SEM unless otherwise indicated.
T-tests were performed using Microsoft Excel to determine
statistical significance of treatment sets. For multiple comparisons,
ANOVA was performed, followed by post-hoc Tukey tests, using
Graphpad InStat to determine statistical significance. Alpha values
were 0.05 except when adjusted by the post-hoc tests.
Supporting Information
Figure S1 8-Br-cAMP upregulates PORE target genes. Gel
images in Figure 3E were quantified by densitometry. Gene
expression values were normalized to GAPDH and standardized
to untreated levels (time 0). The legend indicates time points in
hours.
Found at: doi:10.1371/journal.pone.0004467.s001 (0.28 MB TIF)
Table S1 List of PORE genes.
Found at: doi:10.1371/journal.pone.0004467.s002 (0.07 MB
XLS)
Table S2 Verified Oct4 PORE targets
Found at: doi:10.1371/journal.pone.0004467.s003 (0.03 MB
XLS)
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